Article and Video CATEGORIES
***Speaker Highlights***
for full faculty bio's, please visit our FACULTY page
Learn about Nathan Pennell, MD, PhD, Cleveland Clinic Taussig Cancer Center.
Dr. Pennell is a board certified medical oncologist who joined the staff of the Taussig Cancer Center in 2008. He specializes in the treatment of thoracic malignancies with a focus on lung cancer, and was appointed director of the TCI lung cancer medical oncology program in 2010. He is an associate professor medical oncology at the Cleveland Clinic Lerner College. Dr. Pennell's research interests include clinical trials using novel therapies, with a goal of facilitating the movement of new treatments from the laboratory to the clinic. He received his Ph.D. in neuroscience in 1998 and his M.D. in 2002 from the University of Florida College of Medicine in Gainesville, FL. Dr. Pennell completed his internal medicine residency in 2005 at Brigham and Women's Hospital in Boston, MA. His medical oncology fellowship training was completed in 2007 at the Dana-Farber Cancer Institute.
Dr. Pennell is a long time friend of GRACE, having provided much insight and caring discussion in our forums and posts throughout the years. We are thrilled to have him as a part of the upcoming Targeted Therapies Forum.
For a sampling of GRACE videos that feature Dr. Pennell, please visit here!
Targeted Therapies in Lung Cancer Patient Forum
September 16, 2017
Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center
See below for our growing list of topics and presenters!
Register at cancerGRACE.org | Agenda is subject to change
| 8:30 – 10:00 am | The Many Faces of Progression Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies Dr. Karen Reckamp, City of Hope |
|
| 10:30 – noon |
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West
|
|
|
BREAKOUT SESSIONS |
||
|
1:00 – 2:30 pm
|
Presentations by Lung Cancer Sub-type *Available treatment options *Acquired resistance: How do you pick your next treatment? ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient
|
|
|
BREAKOUT SESSIONS |
||
|
2:50 – 4:00 pm
|
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger
|
|
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…